Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -6.03% is 135% below its 5-year average of 17.06%, near the low end of its 5-year range (-6.03%–65.02%).
As of the fiscal period ended Wednesday, December 31, 2025. 52.47% below its 12-month average of -3.96%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
-6.03%
RETURN ON ASSETS (ROA) AVG TTM
-3.96%
RETURN ON ASSETS (ROA) AVG 3Y
9.16%
RETURN ON ASSETS (ROA) AVG 5Y
17.06%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-52.47%
CURRENT VS 3Y AVG
-165.79%
CURRENT VS 5Y AVG
-135.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.93%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-222.31%
vs the sector median at left
BioNTech SE
Market Cap
$22.59B
Return on Assets (ROA)
-6.03%
TTM Avg
-3.96%
3Y Avg
9.16%
5Y Avg
17.06%
Market Cap
$22.43B
Return on Assets (ROA)
19.17%
TTM Avg
16.59%
3Y Avg
14.73%
5Y Avg
13.22%
Market Cap
$23.10B
Return on Assets (ROA)
13.86%
TTM Avg
12.54%
3Y Avg
14.20%
5Y Avg
14.86%
Market Cap
$23.51B
Return on Assets (ROA)
19.51%
TTM Avg
9.54%
3Y Avg
8.43%
5Y Avg
7.44%
Market Cap
$21.45B
Return on Assets (ROA)
-27.80%
TTM Avg
-24.02%
3Y Avg
-10.32%
5Y Avg
-0.33%
Market Cap
$24.34B
Return on Assets (ROA)
4.93%
TTM Avg
4.41%
3Y Avg
4.42%
5Y Avg
6.18%
Market Cap
$24.42B
Return on Assets (ROA)
1.83%
TTM Avg
13.34%
3Y Avg
15.53%
5Y Avg
17.15%
Market Cap
$20.08B
Return on Assets (ROA)
-0.80%
TTM Avg
-5.49%
3Y Avg
-1.68%
5Y Avg
-1.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | $22.59B | -6.03% | -3.96% | 9.16% | 17.06% |
| United Therapeutics Corporation (UTHR)vs › | $22.43B | 19.17% | 16.59% | 14.73% | 13.22% |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.10B | 13.86% | 12.54% | 14.20% | 14.86% |
| Incyte Corporation (INCY)vs › | $23.51B | 19.51% | 9.54% | 8.43% | 7.44% |
| Moderna, Inc. (MRNA)vs › | $21.45B | -27.80% | -24.02% | -10.32% | -0.33% |
| STERIS plc (STE)vs › | $20.86B | 7.29% | 6.68% | 4.44% | 4.33% |
| Labcorp Holdings Inc. (LH)vs › | $24.34B | 4.93% | 4.41% | 4.42% | 6.18% |
| Waters Corporation (WAT)vs › | $24.42B | 1.83% | 13.34% | 15.53% | 17.15% |
| Viatris Inc. (VTRS)vs › | $20.08B | -0.80% | -5.49% | -1.68% | -1.68% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.15B | 8.21% | 5.75% | 6.24% | 8.30% |
ROA
-6.0%
ROE
-6.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -4.96% |
| 2024-12-31 | -2.95% |
| 2023-12-31 | 4.04% |
| 2022-12-31 | 40.53% |
| 2021-12-31 | 65.02% |
| 2020-12-31 | 0.66% |
| 2019-12-31 | -22.45% |
| 2018-12-31 | -7.35% |
| 2017-12-31 | -22.86% |
| 2016-12-31 | 0.00% |
